Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 28

Sort by

Sort Order Select

Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Cancer Res (2023) 83 (23): 3989–4004.

https://doi.org/10.1158/0008-5472.CAN-23-0694

Published: 01 December 2023

View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Includes: Supplementary data

Journal Articles

Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response

Wael Traboulsi, Subhadip Kundu, Pankaj Gaur, Zainab Ramlaoui, Dareen Sarhan, Nour Shobaki, Jacob Lee, Nazli Jafarzadeh, Simon T. Barry, Viia E. Valge-Archer, Vivek Verma, Seema Gupta, Samir N. Khleif

Cancer Res (2023) 83 (8_Supplement): LB339.

https://doi.org/10.1158/1538-7445.AM2023-LB339

Published: 14 April 2023

View article titled, Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response

Journal Articles

Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Deanna A. Mele, Neil Grimster, Gayathri Bommakanti, Jason Shields, Lucas Morrill, Kathryn Giblin, Maryann SanMartin, Yanjun Wang, Minwei Ye, Iswarya KarapaReddy, Kun Song, Theresa Proia, Niresh Hariparsad, Ryan Richards, Nadia Luheshi, Simon T. Barry, Stephen Fawell

Cancer Res (2023) 83 (7_Supplement): 3453.

https://doi.org/10.1158/1538-7445.AM2023-3453

Published: 04 April 2023

View article titled, Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Journal Articles

Abstract A010: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

Cancer Res (2022) 82 (22_Supplement): A010.

https://doi.org/10.1158/1538-7445.PANCA22-A010

Published: 15 November 2022

View article titled, Abstract A010: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

Journal Articles

Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8⁺ T cells, enhances stem cell-like memory CD8⁺ T cells, and leads to strong anti-tumor activity

Pankaj Gaur, Vivek Verma, Mays Alreem Elayyan, Zainab Ramlaoui, Simon T. Barry, Viia E. Valge-Archer, Paul D. Smith, Seema Gupta, Samir N. Khleif

Cancer Res (2022) 82 (12_Supplement): 4217.

https://doi.org/10.1158/1538-7445.AM2022-4217

Published: 15 June 2022

View article titled, Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8+ T cells, enhances stem cell-like memory CD8+ T cells, and leads to strong anti-tumor activity

Journal Articles

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Maneesh Singh, Laura Bradshaw, Laura B. Prickett, Griffin Matthew, Maryann San Martin, Noel Monks, Lisa Drew, Simon T. Barry, Corinne Reimer, Theresa Proia

Cancer Res (2021) 81 (13_Supplement): 1813.

https://doi.org/10.1158/1538-7445.AM2021-1813

Published: 01 July 2021

View article titled, Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Journal Articles

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

Miriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, María L. Suárez-Solís, Luis C. Fernández, Enrique Carrillo-de-Santa-Pau, Natalia del Pozo, Jaime Martínez de Villarreal, Clément Meiller, Yves Allory, Yuna Blum, Christine Pirker, Balazs Hegedus, Simon T. Barry, Amancio Carnero, Walter Berger, Didier Jean, Francisco X. Real

Cancer Res (2020) 80 (4): 843–856.

https://doi.org/10.1158/0008-5472.CAN-19-1633

Published: 14 February 2020

View article titled, Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

Includes: Supplementary data

Journal Articles

Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer

Charles Sinclair, Alexey S. Revenko, R B. Johnson, Alison Peter, Molly A. Taylor, Lisa A. Hettrick, Stephanie Klein, Anisha Solanki, Melissa Chapman, James Yates, Helen K. Angell, Andrew Watt, Danielle Gattis, Brett P. Monia, Simon T. Barry, Paul Lyne, Mark Edbrooke, Frederick Goldberg, A R. Macleod

Cancer Res (2019) 79 (13_Supplement): 2713.

https://doi.org/10.1158/1538-7445.AM2019-2713

Published: 01 July 2019

View article titled, Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer

Journal Articles

Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

Larissa S. Carnevalli, Danielle Carrol, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Molly A. Taylor, Antonio Montoya, Adina Hughes, Matthew King, Teresa Klinowska, Simon T. Barry

Cancer Res (2019) 79 (13_Supplement): 100.

https://doi.org/10.1158/1538-7445.AM2019-100

Published: 01 July 2019

View article titled, Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

Journal Articles

Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib

Francesca Bizzaro, Alessia C. Marchetti, Alessandra Decio, Francesca Ricci, Mark J. O'Connor, Molly A. Taylor, Zhongwu Lai, Simon T. Barry, Maria R. Bani, Raffaella Giavazzi

Cancer Res (2018) 78 (13_Supplement): 2816.

https://doi.org/10.1158/1538-7445.AM2018-2816

Published: 01 July 2018

View article titled, Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib

Journal Articles

Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

Vivek Verma, Shamim Ahmad, Peng Zeng, Mikayel Mkrtichyan, Simon T. Barry, Paul D. Smith, Paulo C. Rodriguez, John E. Janik, Seema Gupta, Samir N. Khleif

Cancer Res (2018) 78 (13_Supplement): 4717.

https://doi.org/10.1158/1538-7445.AM2018-4717

Published: 01 July 2018

View article titled, Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

Journal Articles

Abstract 311: Development of AZD2811, an aurora kinase B inhibitor, incorporated into an Accurin^TM nanoparticle for use in haematological and solid cancers

Cancer Res (2017) 77 (13_Supplement): 311.

https://doi.org/10.1158/1538-7445.AM2017-311

Published: 01 July 2017

View article titled, Abstract 311: Development of AZD2811, an aurora kinase B inhibitor, incorporated into an AccurinTM nanoparticle for use in haematological and solid cancers

Journal Articles

Abstract B53: The integrin αvβ6 is a promising therapeutic target for treating PDAC

Sabari Vallath, Claire Reader, Jennifer Morton, Owen Sansom, Jeff Evans, Andrew Biankin, Simon T. Barry, Hemant Kocher, John F. Marshall

Cancer Res (2016) 76 (24_Supplement): B53.

https://doi.org/10.1158/1538-7445.PANCA16-B53

Published: 14 December 2016

View article titled, Abstract B53: The integrin αvβ6 is a promising therapeutic target for treating PDAC

Journal Articles

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

David R. Driscoll, Saadia A Karim, Makoto Sano, David M. Gay, Wright Jacob, Jun Yu, Yusuke Mizukami, Aarthi Gopinathan, Duncan I. Jodrell, T.R. Jeffry Evans, Nabeel Bardeesy, Michael N. Hall, Brian J. Quattrochi, David S. Klimstra, Simon T. Barry, Owen J. Sansom, Brian C. Lewis, Jennifer P. Morton

Cancer Res (2016) 76 (23): 6911–6923.

https://doi.org/10.1158/0008-5472.CAN-16-0810

Published: 30 November 2016

View article titled, mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Includes: Supplementary data

Journal Articles

Abstract 4862: PredICT: a novel solution for capturing, assembling and combining in vivo data

Rhys DO Jones, Marie Cooke, James Hinchliffe, Justin Morley, Simon T. Barry

Cancer Res (2015) 75 (15_Supplement): 4862.

https://doi.org/10.1158/1538-7445.AM2015-4862

Published: 01 August 2015

View article titled, Abstract 4862: PredICT: a novel solution for capturing, assembling and combining in vivo data

Journal Articles

Abstract 4524: A preclinical PKPD modeling & simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents

Rhys DO Jones, Rajesh Odedra, James WT Yates, Pablo Morentin Gutierrez, Barry Davies, Kevin Hudson, Simon T. Barry

Cancer Res (2015) 75 (15_Supplement): 4524.

https://doi.org/10.1158/1538-7445.AM2015-4524

Published: 01 August 2015

View article titled, Abstract 4524: A preclinical PKPD modeling & simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents

Journal Articles

Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors

Urs Hancox, Urszula Polanska, James T. Lynch, Carol Lenaghan, Cath Trigwell, Oona Depuelch, Phillippa Dudley, Juliana Maynard, Lara Ward, Kevin Hudson, Jon Curwen, Francisco Cruzalegui, Stephen Green, Klinowska Teresa, Simon T. Barry

Cancer Res (2015) 75 (15_Supplement): 4696.

https://doi.org/10.1158/1538-7445.AM2015-4696

Published: 01 August 2015

View article titled, Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors

Journal Articles

Abstract 3102: AZD1152HQPA Accurin™ nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer

Susan Ashton, Paula Taylor, Nicola Curtis, James Pilling, Thierry Dorval, Jeff Hrkach, Philip J. Jewsbury, Simon T. Barry

Cancer Res (2015) 75 (15_Supplement): 3102.

https://doi.org/10.1158/1538-7445.AM2015-3102

Published: 01 August 2015

View article titled, Abstract 3102: AZD1152HQPA Accurin™ nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer

Journal Articles

Abstract 3678: Imaging AZD1152HQPA Accurin™ nanoparticle accumulation in preclinical tumors

Richard Goodwin, John Swales, Anna Nilsson, Per Andren, Nicola Strittmatter, Zoltan Takats, Colin Howes, Paula Taylor, Susan Ashton, Philip Jewsbury, Simon T. Barry

Cancer Res (2015) 75 (15_Supplement): 3678.

https://doi.org/10.1158/1538-7445.AM2015-3678

Published: 01 August 2015

View article titled, Abstract 3678: Imaging AZD1152HQPA Accurin™ nanoparticle accumulation in preclinical tumors

Journal Articles

Abstract 4249: The Pi3Kβ/δ inhibitor AZD8186 has potential to treat tumours in combination with key signalling pathway inhibitors

Simon T. Barry, Kathryn Cronin, Marie Cumberbatch, Rebecca Ellston, Emily Foster, Urs Hancox, Lyndsey Hanson, Liz Harrington, Carol Lenaghan, Stefan Symeonides, Cath Trigwell, Lara Ward

Cancer Res (2014) 74 (19_Supplement): 4249.

https://doi.org/10.1158/1538-7445.AM2014-4249

Published: 01 October 2014

View article titled, Abstract 4249: The Pi3Kβ/δ inhibitor AZD8186 has potential to treat tumours in combination with key signalling pathway inhibitors

NARROW

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response

Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Abstract A010: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8⁺ T cells, enhances stem cell-like memory CD8⁺ T cells, and leads to strong anti-tumor activity

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer

Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib

Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

Abstract 311: Development of AZD2811, an aurora kinase B inhibitor, incorporated into an Accurin^TM nanoparticle for use in haematological and solid cancers

Abstract B53: The integrin αvβ6 is a promising therapeutic target for treating PDAC

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Abstract 4862: PredICT: a novel solution for capturing, assembling and combining in vivo data

Abstract 4524: A preclinical PKPD modeling & simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents

Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors

Abstract 3102: AZD1152HQPA Accurin™ nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer

Abstract 3678: Imaging AZD1152HQPA Accurin™ nanoparticle accumulation in preclinical tumors

Abstract 4249: The Pi3Kβ/δ inhibitor AZD8186 has potential to treat tumours in combination with key signalling pathway inhibitors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only